<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metolazone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metolazone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Metolazone: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="10863" href="/d/html/10863.html" rel="external">see "Metolazone: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12604" href="/d/html/12604.html" rel="external">see "Metolazone: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867542"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zaroxolyn</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F195738"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diuretic, Thiazide-Related</li></ul></div>
<div class="block doa drugH1Div" id="F195711"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65ef282d-23a6-4668-9e37-3d9d9236ddb8">Edema or general volume overload</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema or general volume overload (adjunctive to loop diuretic):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Optimize loop diuretic therapy before adding metolazone; combination diuretic therapy is typically for short-term use to restore euvolemia in patients already taking high-dose loop diuretic therapy who are resistant (eg, furosemide total daily dose of 160 to 320 mg/day IV or the oral equivalent). Combination diuretic therapy can cause severe electrolyte depletion (eg, potassium, magnesium, sodium); prior to and during therapy, electrolytes should be monitored and appropriately repleted or managed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31526538','lexi-content-ref-35363499','lexi-content-ref-22099505','lexi-content-ref-Brater.1','lexi-content-ref-21029871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31526538','lexi-content-ref-35363499','lexi-content-ref-22099505','lexi-content-ref-Brater.1','lexi-content-ref-21029871'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 2.5 to 5 mg once daily; may increase dose as needed up to a maximum of 20 mg/day in 1 to 2 divided doses depending on patient response; may administer every other day or on specific days of the week; may be administered in combination with or shortly before the scheduled loop diuretic. Assess volume status frequently (eg, daily or at least every 2 to 3 days) to determine effectiveness and to avoid over diuresis. Continue until euvolemia is restored, although some patients may require scheduled treatment for maintenance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31526538','lexi-content-ref-35363499','lexi-content-ref-Brater.1','lexi-content-ref-21029871','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31526538','lexi-content-ref-35363499','lexi-content-ref-Brater.1','lexi-content-ref-21029871','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991854"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Metolazone undergoes minimal hepatic metabolism; the primary route of clearance is excretion of unchanged drug in the urine. Plasma concentrations are expected to be increased with kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4853601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4853601'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33637192','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33637192','lexi-content-ref-Expert.DOR'])">Ref</a></span>). When used in combination with loop diuretics to augment diuresis, due to prolonged half-life, dosing frequency may be adjusted based on patient-specific diuretic needs (eg, administration every other day or 2 times per week). Additionally, if diuresis is too rapid, temporarily holding the dose until the diuresis has diminished (as opposed to continuing therapy with a decreased dose) may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8882303','lexi-content-ref-22183505']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8882303','lexi-content-ref-22183505'])">Ref</a></span>). Close monitoring of electrolytes and volume status is necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33637192']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33637192'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (90% to 95% protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20016467','lexi-content-ref-4853601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20016467','lexi-content-ref-4853601'])">Ref</a></span>). In general, use is not recommended due to lack of efficacy. Consider loop diuretic in patients with residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). In general, use not recommended due to lack of efficacy. Consider loop diuretic in patients with residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> In general, use is not recommended; fluid management can be more effectively managed using CRRT ultrafiltration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> In general, use is not recommended; fluid management can be more effectively managed using PIRRT ultrafiltration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989149"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; contraindicated in hepatic coma or precoma.</p></div>
<div class="block doe drugH1Div" id="F195712"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812533"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12604" href="/d/html/12604.html" rel="external">see "Metolazone: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60d606b1-dbb1-46d5-8f72-533d106a9750">Edema, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Edema, refractory: </b>Limited data available: Infants, Children, and Adolescents: Oral: Usual range: 0.2 to 0.4 mg/kg/day divided every 12 to 24 hours in combination with furosemide; adjust dose to minimal effective dose for maintenance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6493882','lexi-content-ref-Nelson.1996','lexi-content-ref-28889825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6493882','lexi-content-ref-Nelson.1996','lexi-content-ref-28889825'])">Ref</a></span>); maximum adult daily dose: 20 mg/<b>day</b>. <b>Note:</b> Published efficacy of metolazone in infants and children are limited; underlying disease state, renal function, and concomitant therapies all may affect response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6493882','lexi-content-ref-28889825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6493882','lexi-content-ref-28889825'])">Ref</a></span>). According to the manufacturer, a lower dose of 0.05 to 0.1 mg/kg once daily has also been reported to result in weight loss and increase urine output in some pediatric patients.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729772"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use caution in patients with severe kidney impairment, as most of the drug is excreted by the kidney and accumulation may occur.</p></div>
<div class="block dohp drugH1Div" id="F52729773"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; contraindicated in hepatic coma or precoma.</p></div>
<div class="block arsc drugH1Div" id="F58656580"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Electrolyte disturbances</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Reversible <b>hypokalemia</b> and <b>hypomagnesemia</b> may occur with metolazone and may increase the risk of arrhythmias. Contraction alkalosis, <b>hypercalcemia</b>, and <b>hyponatremia</b> can also occur; hyponatremia, in severe cases, can lead to seizures or coma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28419981','lexi-content-ref-31606239','lexi-content-ref-22099511','lexi-content-ref-12671341']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28419981','lexi-content-ref-31606239','lexi-content-ref-22099511','lexi-content-ref-12671341'])">Ref</a></span>). Electrolyte disturbances may be more significant with longer-acting agents (eg, metolazone, chlorthalidone) as compared to shorter-acting thiazide diuretics (eg, hydrochlorothiazide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32065600','lexi-content-ref-21896142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32065600','lexi-content-ref-21896142'])">Ref</a></span>). Development of electrolyte disturbances may be minimized when used in combination with other electrolyte-sparing antihypertensives (eg, angiotensin-converting enzyme, angiotensin receptor blockers, or aldosterone inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21896142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21896142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Thiazide and thiazide-related diuretics block the NaCl cotransporter in the distal convoluted tubule, leading to decreased reabsorption of sodium and chloride and increased delivery of sodium to the collecting duct, which leads to increased potassium wasting. Diluting capacity of the kidney is also impaired, leading to decreased magnesium and increased calcium concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24243991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24243991'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; hypokalemia generally occurs within 2 weeks of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22099511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22099511'])">Ref</a></span>). Hyponatremia onset may range from 2 weeks to 10 years after treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22017784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22017784'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High doses or concurrent loop diuretic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-635611','lexi-content-ref-30371181','lexi-content-ref-21896142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-635611','lexi-content-ref-30371181','lexi-content-ref-21896142'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypokalemia: GI losses (eg, vomiting, diarrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22783025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22783025'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypomagnesemia: Heart failure, poor magnesium intake, high alcohol intake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653441']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653441'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hyponatremia: Increased water intake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22783025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22783025'])">Ref</a></span>); older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3520260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3520260'])">Ref</a></span>); females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28419981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28419981'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypercalcemia: Older patients, females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17904464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17904464'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity reactions, both immediate (eg, <b>urticaria</b>, angioedema) and delayed, have been reported. Delayed hypersensitivity reactions range from skin rash to rare severe cutaneous adverse reactions, including<b> toxic epidermal necrolysis</b> (TEN) and <b>Stevens-Johnson syndrome</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27134890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27134890'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Immediate hypersensitivity reactions: Non–dose-related; immunologic (ie, IgE-mediated, with specific antibodies formed against a drug allergen following initial exposure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30275849'])">Ref</a></span>). Delayed hypersensitivity reactions: Non–dose-related; immunologic (ie, involving a T-cell mediated drug-specific immune response) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Immediate hypersensitivity reactions: Rapid; generally occur within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.1'])">Ref</a></span>). Delayed hypersensitivity reactions: Varied; typically occur days to 6 weeks after drug exposure, but may occur more rapidly (usually within 1 to 4 days) upon reexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26120552','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26120552','lexi-content-ref-NICE.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity: Limited published information regarding possible cross-reactivity between thiazide diuretics and other sulfonamides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20108448','lexi-content-ref-17296538','lexi-content-ref-1984112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20108448','lexi-content-ref-17296538','lexi-content-ref-1984112'])">Ref</a></span>). Cross-reactivity due to antibody production (anaphylaxis) is unlikely to occur with nonantibiotic sulfonamides and antibiotic sulfonamides (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31495421']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31495421'])">Ref</a></span>). Cross-reactivity among thiazide diuretics is unknown.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypotension</b>, including <b>orthostatic hypotension</b>, may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3520260','lexi-content-ref-32639593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3520260','lexi-content-ref-32639593'])">Ref</a></span>). The occurrence of hypotension may be dose-limiting or result in treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4579972','lexi-content-ref-6796191']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4579972','lexi-content-ref-6796191'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, volume depletion) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3520260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3520260'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; hypotension may occur following a single dose, especially when combined with loop diuretic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6796191']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6796191'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of barbiturates, narcotics, or other hypotensive agents</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent loop diuretic therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bataclan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bataclan.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3520260']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3520260'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F195675"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, chest pain, necrotizing angiitis, palpitations, syncope, venous thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, purpuric rash, skin necrosis, skin photosensitivity, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acute gout attack, hyperglycemia, hyperuricemia, hypochloremic alkalosis, hypomagnesemia, hypophosphatemia, hypovolemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, bloating, constipation, diarrhea, epigastric distress, nausea, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction, glycosuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, hemoconcentration, hypoplastic anemia, leukopenia, petechia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, chills, depression with psychosis, dizziness, drowsiness, fatigue, headache, neuropathy, paresthesia, restlessness, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, muscle cramps, muscle spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Transient blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (Steuber 2020), orthostatic hypotension (Bennett 1973)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome (Kumar 2016), toxic epidermal necrolysis (Kumar 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercalcemia (Anderson 1992), hypochloremia (Steuber 2020), hypokalemia (Steuber 2020), hyponatremia (Steuber 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis (Anderson 1991)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (Donovan 1989)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (Steuber 2020)</p></div>
<div class="block coi drugH1Div" id="F195690"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to metolazone or any component of the formulation; anuria; hepatic coma or precoma.</p></div>
<div class="block war drugH1Div" id="F195672"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide ("sulfa") allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or at the very least this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal insufficiency: Avoid use of diuretics for treatment of elevated blood pressure in patients with primary adrenal insufficiency (Addison disease). Adjustment of glucocorticoid/mineralocorticoid therapy and/or use of other antihypertensive agents is preferred to treat hypertension (Bornstein 2016; Inder 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Dehydration: Avoid diuretics in the immediate postoperative period after bariatric surgery; electrolyte disturbances and dehydration may occur. Diuretics may be resumed, if indicated, once oral fluid intake goals are met (Ziegler 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gout: Hyperuricemia can occur and gout can be precipitated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution in severe renal disease. If azotemia and oliguria worsen during treatment in these patients, discontinue therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Systemic lupus erythematosus (SLE): Can cause SLE exacerbation or activation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: If given the morning of surgery, metolazone may render the patient volume depleted and blood pressure may be labile during general anesthesia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Interchangeability: Do not interchange Zaroxolyn with other formulations of metolazone that are not therapeutically equivalent at the same doses (eg, Mykrox, no longer available in the US).</p></div>
<div class="block foc drugH1Div" id="F195682"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg, 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F195668"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F195693"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (metOLazone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $0.19 - $3.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.27 - $4.26</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.36 - $3.51</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867543"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zaroxolyn: 2.5 mg</p></div>
<div class="block adm drugH1Div" id="F195686"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer as a single daily dose with or without food. Therapy should be taken early in the day to avoid nocturia.</p></div>
<div class="block admp drugH1Div" id="F52613317"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer early in day to avoid nocturia.</p></div>
<div class="block use drugH1Div" id="F195685"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Edema or general volume overload:</b> Treatment of edema due to heart failure or renal diseases, including the nephrotic syndrome and states of diminished renal function.</p></div>
<div class="block mst drugH1Div" id="F195746"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MetOLazone may be confused with metaxalone, methadone, methazolAMIDE, methIMAzole, methotrexate, metoclopramide, metoprolol, minoxidil</p>
<p style="text-indent:-2em;margin-left:4em;">Zaroxolyn may be confused with Zarontin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Diuretics are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299705"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F195677"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: Thiazide and Thiazide-Like Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Thiazide and Thiazide-Like Diuretics may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May increase the serum concentration of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Thiazide and Thiazide-Like Diuretics may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arsenic Trioxide: Thiazide and Thiazide-Like Diuretics may enhance the hypotensive effect of Arsenic Trioxide. Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as the thiazide and thiazide-like diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Thiazide and Thiazide-Like Diuretics. The diuretic response is likewise decreased. Management: Consider separating administraton of bile acid sequestrants and thiazide diuretics by at least 4 hours. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Calcium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of thiazide diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, granulocytopenia may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Diazoxide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Thiazide and Thiazide-Like Diuretics may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Dofetilide.  Management: Although hydrochlorothiazide is specifically cited as a contraindication, the risk likely extends to all thiazide and thiazide-like diuretics and may be even greater with chlorthalidone or bendroflumethiazide. Consider alternatives when possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipragliflozin: May enhance the adverse/toxic effect of Thiazide and Thiazide-Like Diuretics. Specifically, the risk for intravascular volume depletion may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Thiazide and Thiazide-Like Diuretics may enhance the arrhythmogenic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Thiazide and Thiazide-Like Diuretics may decrease the excretion of Lithium.  Management: Reduce the lithium dose if coadministered with thiazide or thiazide-like diuretics. Monitor serum lithium levels during coadministration with thiazide and thiazide-like diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Thiazide and Thiazide-Like Diuretics may enhance the adverse/toxic effect of Mecamylamine.  Management: Consider avoiding the use of mecamylamine and thiazide diuretics. If combined, mecamylamine prescribing information suggests reducing the mecamylamine dose by 50% in order to avoid excessive hypotension.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: Thiazide and Thiazide-Like Diuretics may diminish the therapeutic effect of Methenamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the hypercalcemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, thiazide diuretics may decrease the excretion of calcium, and continued concomitant use can also result in metabolic alkalosis. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Thiazide and Thiazide-Like Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Thiazide and Thiazide-Like Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Diuretics may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Thiazide and Thiazide-Like Diuretics may enhance the QTc-prolonging effect of Promazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: May enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Thiazide and Thiazide-Like Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: Thiazide and Thiazide-Like Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F3343861"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Metolazone crosses the placenta and appears in cord blood.</p>
<p style="text-indent:0em;margin-top:2em;">Hypoglycemia, hypokalemia, hyponatremia, jaundice, and thrombocytopenia are reported as complications to the fetus or newborn following maternal use of thiazide diuretics.</p>
<p style="text-indent:0em;margin-top:2em;">Use to treat edema during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor.</p></div>
<div class="block brc drugH1Div" id="F20616314"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Metolazone is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F195694"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May require potassium supplementation</p></div>
<div class="block mop drugH1Div" id="F195680"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum electrolytes, uric acid, fluid balance, renal function, blood pressure (standing, sitting/supine).</p></div>
<div class="block pha drugH1Div" id="F195671"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water, as well as, potassium and hydrogen ions</p></div>
<div class="block phk drugH1Div" id="F195689"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Diuresis: ~60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: ≥24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 113 L (Ernst 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 95% (Ernst 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 65% (Ernst 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 8 to 14 hours (Ernst 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (80%) (Ernst 2009).</p></div>
<div class="block phksp drugH1Div" id="F51159496"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-4em;margin-left:4em;">Altered kidney function: Accumulation may occur in severe renal impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038678"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Merozolyn | Metolaz</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Metolazon | Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Pavedal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Demafight | Efectinix | Metolanix</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Barolyn | Metolazon abcur</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Metenix | Xaqua | Xuret | Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Metenix | Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Diulo | Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Diurem | Lazon | Mela | Metadure | Metolaz | Metoz | Metozide | Zalat | Zytanix</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Normelan</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Metoz</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Metonic | Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Metolazon abcur | Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Metoz</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Metxone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Mykrox | Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Diulo | Metolazona</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Metolazon abcur | Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Diulo | Mycros | Mykrox | Mykyo | Rixia | Zaroxolyn</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Metoz</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Zaroxolyn</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1928234">
<a name="1928234"></a>Anderson PE, Ellis GG Jr, Austin SM. Case report: metolazone-associated hypercalcemia and acute pancreatitis. <i>Am J Med Sci</i>. 1991;302(4):235-237. doi: 10.1097/00000441-199110000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/1928234/pubmed" id="1928234" target="_blank">1928234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20108448">
<a name="20108448"></a>Aouam K, Ali HB, Youssef M, et al. Lichenoid eruption associated with hydrochlorothiazide and possible cross reactivity to furosemide. <i>Therapie</i>. 2009;64(5):344-347. doi: 10.2515/therapie/2009050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/20108448/pubmed" id="20108448" target="_blank">20108448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6493882">
<a name="6493882"></a>Arnold WC, “Efficacy of Metolazone and Furosemide in Children With Furosemide-Resistant Edema,” <i>Pediatrics</i>, 1984, 74(5):872-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/6493882/pubmed" id="6493882" target="_blank">6493882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bataclan.1">
<a name="Bataclan.1"></a>Bataclan RP, Alonso RS. Metolazone and furosemide combination in cardiorenal syndrome: short-term safety and efficacy among admitted patients in a tertiary hospital. <i>JOJ Urology and Nephrology</i>. 2019; 6(3): 43-48.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4579972">
<a name="4579972"></a>Bennett WM, Porter GA. Efficacy and safety of metolazone in renal failure and the nephrotic syndrome. <i>J Clin Pharmacol</i>. 1973;13(8):357-364. doi:10.1002/j.1552-4604.1973.tb00224.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/4579972/pubmed" id="4579972" target="_blank">4579972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-635611">
<a name="635611"></a>Black WD, Shiner PT, Roman J. Severe electrolyte disturbances associated with metolazone and furosemide. <i>South Med J</i>. 1978;71(4):380-381, 385. doi:10.1097/00007611-197804000-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/635611/pubmed" id="635611" target="_blank">635611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22099505">
<a name="22099505"></a>Brater DC. Update in diuretic therapy: clinical pharmacology. <i>Semin Nephrol</i>. 2011;31(6):483-494. doi:10.1016/j.semnephrol.2011.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/22099505/pubmed" id="22099505" target="_blank">22099505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brater.1">
<a name="Brater.1"></a>Brater DC, Ellison DH. Causes and treatment of refractory edema in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed June 2, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30371181">
<a name="30371181"></a>Brisco-Bacik MA, Ter Maaten JM, Houser SR, et al. Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis. <i>J Am Heart Assoc</i>. 2018;7(18):e009149. doi:10.1161/JAHA.118.009149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/30371181/pubmed" id="30371181" target="_blank">30371181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6796191">
<a name="6796191"></a>Brown E, MacGregor G. Synergistic action of metolazone and frusemide. <i>Br Med J (Clin Res Ed)</i>. 1981;283(6306):1611. doi:10.1136/bmj.283.6306.1611-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/6796191/pubmed" id="6796191" target="_blank">6796191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28419981">
<a name="28419981"></a>Burst V, Grundmann F, Kubacki T, et al. Thiazide-associated hyponatremia, report of the Hyponatremia Registry: an observational multicenter international study. <i>Am J Nephrol</i>. 2017;45(5):420-430. doi:10.1159/000471493<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/28419981/pubmed" id="28419981" target="_blank">28419981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8130022">
<a name="8130022"></a>Channer KS, McLean KA, Lawson-Matthew P, et al, “Combination Diuretic Treatment in Severe Heart Failure: A Randomised Controlled Trial,” <i>Br Heart J</i>, 1994, 71(2):146-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/8130022/pubmed" id="8130022" target="_blank">8130022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2508968">
<a name="2508968"></a>Donovan KL. Neutropenia and metolazone. <i>BMJ</i>. 1989;299(6705):981. doi:10.1136/bmj.299.6705.981-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/2508968/pubmed" id="2508968" target="_blank">2508968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19940300">
<a name="19940300"></a>Ernst ME, Moser M. Use of diuretics in patients with hypertension [published correction appears in <i>N Engl J Med</i>. 2010;363(19):1877]. <i>N Engl J Med</i>. 2009;361(22):2153-2164. doi: 10.1056/NEJMra0907219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/19940300/pubmed" id="19940300" target="_blank">19940300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3520260">
<a name="3520260"></a>Field MJ, Lawrence JR. Complications of thiazide diuretic therapy: an update. <i>Med J Aust</i>. 1986;144(12):641-644. doi:10.5694/j.1326-5377.1986.tb112347.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/3520260/pubmed" id="3520260" target="_blank">3520260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31606239">
<a name="31606239"></a>Filippone EJ, Ruzieh M, Foy A. Thiazide-associated hyponatremia: clinical manifestations and pathophysiology.<i> Am J Kidney Dis</i>. 2020;75(2):256-264. doi:10.1053/j.ajkd.2019.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/31606239/pubmed" id="31606239" target="_blank">31606239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10653441">
<a name="10653441"></a>Greenberg A. Diuretic complications. <i>Am J Med Sci</i>. 2000;319(1):10-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/10653441/pubmed" id="10653441" target="_blank">10653441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31526538">
<a name="31526538"></a>Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology solution set oversight committee. <i>J Am Coll Cardiol</i>. 2019;74(15):1966-2011. doi:10.1016/j.jacc.2019.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/31526538/pubmed" id="31526538" target="_blank">31526538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32065600">
<a name="32065600"></a>Hripcsak G, Suchard MA, Shea S, et al. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. <i>JAMA Intern Med</i>. 2020;180(4):542-551. doi:10.1001/jamainternmed.2019.7454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/32065600/pubmed" id="32065600" target="_blank">32065600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25138826">
<a name="25138826"></a>Inder WJ, Meyer C, Hunt PJ. Management of hypertension and heart failure in patients with Addison's disease. <i>Clin Endocrinol (Oxf)</i>. 2015;82(6):789-792. doi: 10.1111/cen.12592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/25138826/pubmed" id="25138826" target="_blank">25138826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21029871">
<a name="21029871"></a>Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. <i>J Am Coll Cardiol</i>. 2010;56(19):1527-1534. doi:10.1016/j.jacc.2010.06.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/21029871/pubmed" id="21029871" target="_blank">21029871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in <i>Ann Pharmacother</i>. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31495421">
<a name="31495421"></a>Khan DA, Knowles SR, Shear NH. Sulfonamide hypersensitivity: fact and fiction. <i>J Allergy Clin Immunol Pract</i>. 2019;7(7):2116-2123. doi:10.1016/j.jaip.2019.05.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/31495421/pubmed" id="31495421" target="_blank">31495421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int</i>. 2021;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27134890">
<a name="27134890"></a>Kumar P, Chauhan A, Charaniya R, Ghosh A, Tandon V. Metolazone associated Stevens Johnson Syndrome-Toxic Epidermal Necrolysis overlap. <i>J Clin Diagn Res</i>. 2016;10(3):FD01-2. doi:10.7860/JCDR/2016/17768.7404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/27134890/pubmed" id="27134890" target="_blank">27134890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22017784">
<a name="22017784"></a>Leung AA, Wright A, Pazo V, Karson A, Bates DW. Risk of thiazide-induced hyponatremia in patients with hypertension. <i>Am J Med</i>. 2011;124(11):1064-1072. doi:10.1016/j.amjmed.2011.06.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/22017784/pubmed" id="22017784" target="_blank">22017784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20016467">
<a name="20016467"></a>Levin NW, Kotanko P, Eckardt KU, et al. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. <i>Kidney Int.</i> 2010;77(4):273-284. doi:10.1038/ki.2009.469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/20016467/pubmed" id="20016467" target="_blank">20016467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Innogenix.1">
<a name="Innogenix.1"></a>Metolazone tablets (metolazone, USP) [prescribing information]. Amityville, NY: Innogenix, LLC; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Drug allergy: diagnosis and management. https://www.nice.org.uk/guidance/cg183. Published September 3, 2014. Accessed September 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1996">
<a name="Nelson.1996"></a>Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22099511">
<a name="22099511"></a>Palmer BF. Metabolic complications associated with use of diuretics. <i>Semin Nephrol</i>. 2011;31(6):542-552. doi:10.1016/j.semnephrol.2011.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/22099511/pubmed" id="22099511" target="_blank">22099511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi: 10.1016/j.jash.2015.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243991">
<a name="24243991"></a>Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. <i>J Cardiovasc Pharmacol Ther</i>. 2014;19(1):5-13. doi:10.1177/1074248413497257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/24243991/pubmed" id="24243991" target="_blank">24243991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17296538">
<a name="17296538"></a>Ruscin JM, Page RL 2nd, Scott J. Hydrochlorothiazide-induced angioedema in a patient allergic to sulfonamide antibiotics: evidence from a case report and a review of the literature. <i>Am J Geriatr Pharmacother</i>. 2006;4(4):325-329. doi 10.1016/j.amjopharm.2006.12.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/17296538/pubmed" id="17296538" target="_blank">17296538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22183505">
<a name="22183505"></a>Sica DA. Diuretic use in renal disease. <i>Nat Rev Nephrol</i>. 2011a;8(2):100-109. doi:10.1038/nrneph.2011.175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/22183505/pubmed" id="22183505" target="_blank">22183505</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12671341">
<a name="12671341"></a>Sica DA. Metolazone and its role in edema management. <i>Congest Heart Fail</i>. 2003;9(2):100-105. doi:10.1111/j.1527-5299.2003.01907.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/12671341/pubmed" id="12671341" target="_blank">12671341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21896142">
<a name="21896142"></a>Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. <i>J Clin Hypertens (Greenwich)</i>. 2011b;13(9):639-643. doi: 10.1111/j.1751-7176.2011.00512.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/21896142/pubmed" id="21896142" target="_blank">21896142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8882303">
<a name="8882303"></a>Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships. <i>Clin Pharmacokinet.</i> 1996;30(3):229-249. doi:10.2165/00003088-199630030-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/8882303/pubmed" id="8882303" target="_blank">8882303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32639593">
<a name="32639593"></a>Steuber TD, Janzen KM, Howard ML. A systematic review and meta-analysis of metolazone compared to chlorothiazide for treatment of acute decompensated heart failure. <i>Pharmacotherapy</i>. 2020;40(9):924-935. doi:10.1002/phar.2440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/32639593/pubmed" id="32639593" target="_blank">32639593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1984112">
<a name="1984112"></a>Sullivan TJ. Cross-reactions among furosemide, hydrochlorothiazide, and sulfonamides. <i>JAMA</i>. 1991;265(1):120-121. doi:10.1001/jama.265.1.120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/1984112/pubmed" id="1984112" target="_blank">1984112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4853601">
<a name="4853601"></a>Tilstone WJ, Dargie H, Dargie EN, Morgan HG, Kennedy AC. Pharmacokinetics of metolazone in normal subjects and in patients with cardiac or renal failure. <i>Clin Pharmacol Ther.</i> 1974;16(2):322-329. doi:10.1002/cpt1974162322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/4853601/pubmed" id="4853601" target="_blank">4853601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30275849">
<a name="30275849"></a>Warrington R, Silviu-Dan F, Wong T. Drug allergy. <i>Allergy Asthma Clin Immunol</i>. 2018;14(Suppl 2):60. doi:10.1186/s13223-018-0289-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/30275849/pubmed" id="30275849" target="_blank">30275849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2184406">
<a name="2184406"></a>Wells TG, “The Pharmacology and Therapeutics of Diuretics in the Pediatric Patient,” <i>Pediatr Clin North Am</i>, 1990, 37(2):463-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/2184406/pubmed" id="2184406" target="_blank">2184406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17904464">
<a name="17904464"></a>Wermers RA, Kearns AE, Jenkins GD, Melton LJ 3rd. Incidence and clinical spectrum of thiazide-associated hypercalcemia. <i>Am J Med</i>. 2007;120(10):911.e9-15. doi:10.1016/j.amjmed.2006.07.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/17904464/pubmed" id="17904464" target="_blank">17904464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22783025">
<a name="22783025"></a>Wile D. Diuretics: a review. <i>Ann Clin Biochem</i>. 2012;49(Pt 5):419-431. doi:10.1258/acb.2011.011281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/22783025/pubmed" id="22783025" target="_blank">22783025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28889825">
<a name="28889825"></a>Wise RT, Moffett BS, Akcan-Arikan A, Galati M, Afonso N, Checchia PA. Enhancement of diuresis with metolazone in infant paediatric cardiac intensive care patients. <i>Cardiol Young</i>. 2018;28(1):27-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/28889825/pubmed" id="28889825" target="_blank">28889825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zaroxolyn.1">
<a name="Zaroxolyn.1"></a>Zaroxolyn (metolazone) [prescribing information]. Smyrna, GA: UCB Inc; January 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20152742">
<a name="20152742"></a>Ziegler O, Sirveaux MA, Brunaud L, Reibel N, Quilliot D. Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. <i>Diabetes Metab</i>. 2009;35(6, pt 2):544-557. doi: 10.1016/S1262-3636(09)73464-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metolazone-drug-information/abstract-text/20152742/pubmed" id="20152742" target="_blank">20152742</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9644 Version 407.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
